Search

Your search keyword '"Tuballes, Kevin"' showing total 107 results

Search Constraints

Start Over You searched for: Author "Tuballes, Kevin" Remove constraint Author: "Tuballes, Kevin"
107 results on '"Tuballes, Kevin"'

Search Results

1. Circulating proteins to predict COVID-19 severity

2. Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c+ B cells

3. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae

4. Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR

5. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy

6. A methylation clock model of mild SARS‐CoV‐2 infection provides insight into immune dysregulation

7. Correction: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

8. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

9. Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children

10. An inflammatory cytokine signature predicts COVID-19 severity and survival

11. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)

12. Supplementary Table 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

13. Supplementary Figure 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

14. Supplementary Figure Legend from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

15. Supplementary Table 1 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

16. Supplementary Figure 3 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

17. Supplementary Figure 1 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

18. Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn’s Disease

19. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy

20. Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c+ B cells.

21. Additional file 6 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

22. Additional file 1 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

23. Additional file 2 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

24. Additional file 3 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

25. Additional file 5 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

26. Tu1897 ASSOCIATION OF ANTI-GRANULOCYTE-MACROPHAGE COLONYSTIMULATING FACTOR ANTIBODIES WITH THE RISK OF CROHN'S DISEASE ONSET AND INTERACTION WITH GUT MICROBIOTA

30. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification

31. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

32. Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment

33. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

34. Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c+B cells

35. Anti–GM-CSF autoantibodies promote a “pre-diseased” state in Crohn’s Disease

36. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

37. Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)

39. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)

40. CITEseq analysis of non-small-cell lung cancer lesions reveals an axis of immune cell activation associated with tumor antigen load and TP53 mutations

41. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)

42. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

43. Sampling the host response to SARS-CoV-2 in hospitals under siege

44. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae

46. Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

47. Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege

48. Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege

49. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

50. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.

Catalog

Books, media, physical & digital resources